title: JAK inhibitors in dermatology: The promise of a new drug class.
abstract: New molecularly targeted therapeutics are changing dermatologic therapy. Janus kinase-signal transducer and activator of transcription (JAK-STAT) is an intracellular signaling pathway upon which many different proinflammatory signaling pathways converge. Numerous inflammatory dermatoses are driven by soluble inflammatory mediators, which rely on JAK-STAT signaling, and inhibition of this pathway using JAK inhibitors might be a useful therapeutic strategy for these diseases. Growing evidence suggests that JAK inhibitors are efficacious in atopic dermatitis, alopecia areata, psoriasis, and vitiligo. Additional evidence suggests that JAK inhibition might be broadly useful in dermatology, with early reports of efficacy in several other conditions. JAK inhibitors can be administered orally or used topically and represent a promising new class of medications. The use of JAK inhibitors in dermatology is reviewed here.
authors.affiliation: Department of Dermatology, Yale School of Medicine, New Haven, Connecticut.
authors.forename: William
authors.initials: W
authors.lastname: Damsky
authors.affiliation: Department of Dermatology, Yale School of Medicine, New Haven, Connecticut. Electronic address: brett.king@yale.edu.
authors.forename: Brett A
authors.initials: BA
authors.lastname: King
mesh_terms: D000506:Alopecia Areata / Q000188:drug therapy / Q000201:enzymology; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001384:Azetidines / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003876:Dermatitis, Atopic / Q000188:drug therapy / Q000201:enzymology; D003879:Dermatologic Agents / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D006801:Humans; D053612:Janus Kinases / Q000037:antagonists & inhibitors*; D058990:Molecular Targeted Therapy; D009570:Nitriles; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy / Q000201:enzymology; D011687:Purines; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use; D011758:Pyrroles / Q000009:adverse effects / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects; D012871:Skin Diseases / Q000188:drug therapy* / Q000201:enzymology; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use; D014820:Vitiligo / Q000188:drug therapy / Q000201:enzymology
chemical_list: D000893:Anti-Inflammatory Agents; D001384:Azetidines; D003879:Dermatologic Agents; D009570:Nitriles; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011687:Purines; D011720:Pyrazoles; D011743:Pyrimidines; D011758:Pyrroles; D013449:Sulfonamides; C540383:ruxolitinib; C479163:tofacitinib; C588062:oclacitinib; D053612:Janus Kinases; C000596027:baricitinib
keywords: JAK inhibitor; JAK-STAT; alopecia areata; atopic dermatitis; baricitinib; psoriasis; ruxolitinib; tofacitinib; vitiligo